{"nctId":"NCT01077024","briefTitle":"Smoking-Cessation and Stimulant Treatment (S-CAST)","startDateStruct":{"date":"2010-02"},"conditions":["Cocaine Dependence","Methamphetamine Dependence","Nicotine Dependence"],"count":538,"armGroups":[{"label":"Smoking-cessation treatment + substance treatment as usual","type":"EXPERIMENTAL","interventionNames":["Other: Smoking-cessation treatment"]},{"label":"Substance-treatment as usual","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Smoking-cessation treatment","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of cocaine/methamphetamine dependence\n* Smoked cigarettes for at least 3 months\n* Currently smoking \\> 6 cigarettes/day\n* Have an interest in quitting smoking\n* Enrolled in outpatient treatment at a participating site\n\nExclusion Criteria:\n\n* Clinical diagnosis of current alcohol or sedative dependence, bipolar disorder; or a life-time diagnosis of anorexia nervosa or bulimia\n* Seeking/receiving treatment for opiate-agonist replacement therapy\n* Medical conditions that could compromise participant safety\n* Taking medications with known/potential interactions with bupropion\n* Hypersensitivity to bupropion, nicotine, or menthol\n* Pregnant or breastfeeding\n* Abnormal ECG\n* Recent smoking cessation treatment\n* Use of tobacco products other than cigarettes in the past week\n* Likely to enter residential/inpatient treatment within 10 weeks\n* Have all stimulant-positive urine drug screens during screening/baseline","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Stimulant-free Weeks Assessed by Self-report and Twice-weekly Urine Drug Screens","description":"Stimulant-free week results (no cocaine, methamphetamine and amphetamine use) were obtained by combining the urine drug screens (UDS) and the self-reported Timeline Follow-Back (TLFB). At the group level, this outcome translates into the percentage of weeks in each study arm that are stimulant-free.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","spread":null},{"groupId":"OG001","value":"78.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Point-prevalence Abstinence (Smoking Outcome)","description":"point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Four Week Continuous Smoking Abstinence","description":"A combination of daily self-reported smoking data and weekly carbon monoxide levels were used to determine continuous abstinence during post-quit days 15 - 42.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Stimulant-free Results at 3-month Visit","description":"At the 3-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.3","spread":null},{"groupId":"OG001","value":"68.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Point-prevalence Abstinence (Smoking Outcome) 3 Month Visit","description":"point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Stimulant-free Results at 6-month Visit","description":"At the 6-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","spread":null},{"groupId":"OG001","value":"71.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Point-prevalence Abstinence (Smoking Outcome) 6 Month Visit","description":"point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":null},{"groupId":"OG001","value":"3.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":267},"commonTop":["Headache","Nasopharyngitis","Toothache","Upper respiratory tract infection","Nausea"]}}}